MA34975B1 - Composition d'inhibiteur viral pour une utilisation therapeutique in vivo. - Google Patents

Composition d'inhibiteur viral pour une utilisation therapeutique in vivo.

Info

Publication number
MA34975B1
MA34975B1 MA36264A MA36264A MA34975B1 MA 34975 B1 MA34975 B1 MA 34975B1 MA 36264 A MA36264 A MA 36264A MA 36264 A MA36264 A MA 36264A MA 34975 B1 MA34975 B1 MA 34975B1
Authority
MA
Morocco
Prior art keywords
therapeutic use
inhibitor composition
vivo therapeutic
viral inhibitor
viral
Prior art date
Application number
MA36264A
Other languages
English (en)
Inventor
Christine Coppens
Original Assignee
Cesa Alliance Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/054758 external-priority patent/WO2011117424A1/fr
Application filed by Cesa Alliance Sa filed Critical Cesa Alliance Sa
Publication of MA34975B1 publication Critical patent/MA34975B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N35/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
    • A01N35/04—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aldehyde or keto groups, or thio analogues thereof, directly attached to an aromatic ring system, e.g. acetophenone; Derivatives thereof, e.g. acetals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
    • A01N37/38—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system
    • A01N37/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system having at least one carboxylic group or a thio analogue, or a derivative thereof, and one oxygen or sulfur atom attached to the same aromatic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C07C49/248—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un composé de formule A, soit (2,3(dihydroxy), 5[3(1,2)butadiène], 1(3hydroxy,3méthyl,4pentène) benzène) et/ou un composé de formule B, soit (2,3(dihydroxy), 5[3(1,2)butadiène]
MA36264A 2011-03-28 2011-09-27 Composition d'inhibiteur viral pour une utilisation therapeutique in vivo. MA34975B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2011/054758 WO2011117424A1 (fr) 2010-03-26 2011-03-28 Compositions inhibitrices virales pour une utilisation thérapeutique in vivo comprenant une combinaison de (-)-carvone, de géraniol et d'un autre composant d'huile essentielle
PCT/EP2011/066746 WO2012038553A1 (fr) 2011-03-28 2011-09-27 Composition d'inhibiteur viral pour une utilisation thérapeutique in vivo

Publications (1)

Publication Number Publication Date
MA34975B1 true MA34975B1 (fr) 2014-03-01

Family

ID=44677899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36264A MA34975B1 (fr) 2011-03-28 2011-09-27 Composition d'inhibiteur viral pour une utilisation therapeutique in vivo.

Country Status (25)

Country Link
US (1) US9315448B2 (fr)
EP (1) EP2691088B1 (fr)
JP (1) JP5701445B2 (fr)
KR (1) KR101818286B1 (fr)
CN (1) CN103458883B (fr)
AU (1) AU2011306879B2 (fr)
BR (1) BR112013024457A2 (fr)
CA (1) CA2830703C (fr)
CO (1) CO6771455A2 (fr)
DK (1) DK2691088T3 (fr)
EA (1) EA025610B1 (fr)
ES (1) ES2538011T3 (fr)
HR (1) HRP20150596T1 (fr)
IL (1) IL228444A (fr)
MA (1) MA34975B1 (fr)
MX (1) MX2013011242A (fr)
NZ (1) NZ615613A (fr)
PL (1) PL2691088T3 (fr)
PT (1) PT2691088E (fr)
RS (1) RS54022B1 (fr)
SG (1) SG193426A1 (fr)
SI (1) SI2691088T1 (fr)
SM (1) SMT201500131B (fr)
UA (1) UA110512C2 (fr)
WO (1) WO2012038553A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112280750B (zh) * 2020-10-22 2022-11-01 山东农业大学 具有跨种传播能力的新型鹅星状病毒及其应用
CN118078795A (zh) * 2024-02-28 2024-05-28 首都医科大学附属北京友谊医院 乙酸异丁香酚酯在制备预防和/或治疗炎症性肠病的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU78955A1 (de) * 1978-01-27 1979-09-06 Chimicasa Gmbh Verfahren zur inaktivierung von viren
US4902678A (en) 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US5128353A (en) 1985-06-20 1992-07-07 University Of Florida Anti-neoplastic, anti-viral and ribonucleotide reductase activity affecting pharmaceutical compositions and methods of treatment
US5856364A (en) 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch

Also Published As

Publication number Publication date
ES2538011T3 (es) 2015-06-16
RS54022B1 (sr) 2015-10-30
IL228444A0 (en) 2013-12-31
HK1188715A1 (en) 2014-05-16
BR112013024457A2 (pt) 2020-09-29
JP2014517809A (ja) 2014-07-24
AU2011306879B2 (en) 2016-08-25
KR20140026417A (ko) 2014-03-05
CA2830703C (fr) 2016-06-14
AU2011306879A1 (en) 2013-10-10
US20140088193A1 (en) 2014-03-27
MX2013011242A (es) 2013-10-17
WO2012038553A1 (fr) 2012-03-29
NZ615613A (en) 2014-10-31
CO6771455A2 (es) 2013-10-15
CN103458883B (zh) 2015-12-16
JP5701445B2 (ja) 2015-04-15
SMT201500131B (it) 2015-07-09
CN103458883A (zh) 2013-12-18
HRP20150596T1 (hr) 2015-08-14
PT2691088E (pt) 2015-07-02
US9315448B2 (en) 2016-04-19
EP2691088A1 (fr) 2014-02-05
CA2830703A1 (fr) 2012-03-29
EA201370181A1 (ru) 2014-01-30
DK2691088T3 (en) 2015-06-15
IL228444A (en) 2016-10-31
UA110512C2 (ru) 2016-01-12
SG193426A1 (en) 2013-10-30
EP2691088B1 (fr) 2015-03-11
SI2691088T1 (sl) 2015-07-31
KR101818286B1 (ko) 2018-01-12
PL2691088T3 (pl) 2015-08-31
EA025610B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
MA35085B1 (fr) Procede de traitement d'une nephropathie induite par les produits de contraste
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA33488B1 (fr) Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
PH12017501306A1 (en) Inhibitors of histone demethylases
MY158757A (en) Viral inhibitor composition for in vivo threpeutic use
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA35716B1 (fr) Formulations pharmaceutiques
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
BR112015007879A2 (pt) inibidores do vírus da hepatite c
MA34840B1 (fr) Dérivés monoterpènes de chalcone ou de dihydrochalcone, et leur utilisation en tant qu'agents de dépigmentation
MA34946B1 (fr) Nouvelles benzodioxolepipérazines
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
TW200745122A (en) New compounds I
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA34975B1 (fr) Composition d'inhibiteur viral pour une utilisation therapeutique in vivo.
MA34709B1 (fr) Compositions pharmaceutiques
TW200745133A (en) New compounds II